(Q41382795)

English

13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study

scientific article published on 23 March 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

sickle-cell disease

0 references

1 reference

based on heuristic

inferred from title

pneumococcal conjugate vaccine

1 reference

based on heuristic

inferred from title

object named as

Baba Inusa

10

0 references

Alberto E. Tozzi

object named as

Alberto Tozzi

16

0 references

object named as

Paul T Heath

12

0 references

Natasha B. Halasa

9

object named as

Natasha Halasa

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

William C. Gruber

19

object named as

William C Gruber

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

author name string

Mariane De Montalembert

1

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Miguel R Abboud

2

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Anne Fiquet

3

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Adlette Inati

4

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Jeffrey D Lebensburger

5

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Normeen Kaddah

6

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Galila Mokhtar

7

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Antonio Piga

8

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

David C Rees

11

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Paul Telfer

13

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Catherine Driscoll

14

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Sami Al Hajjar

15

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Qin Jiang

17

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Emilio A Emini

18

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Alejandra Gurtman

20

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Daniel A Scott

21

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

publication date

23 March 2015

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Pediatric Blood & Cancer

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

62

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

1427-1436

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Sickle Cell Anemia and Severe Infections Due to Encapsulated Bacteria

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25502

21 January 2018

Trends in pediatric sickle cell disease-related mortality in the United States, 1983-2002.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25502

21 January 2018

Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25502

21 January 2018

Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25502

21 January 2018

Invasive pneumococcal disease among children with and without sickle cell disease in the United States, 1998 to 2009.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25502

21 January 2018

Increase in invasive Streptococcus pneumoniae infections in children with sickle cell disease since pneumococcal conjugate vaccine licensure

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25502

21 January 2018

Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue?

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25502

21 January 2018

Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25502

21 January 2018

The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25502

21 January 2018

13-Valent pneumococcal conjugate vaccine in older children and adolescents either previously immunized with or naïve to 7-valent pneumococcal conjugate vaccine

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25502

21 January 2018

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25502

21 January 2018

Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25502

21 January 2018

Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25502

21 January 2018

Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25502

21 January 2018

Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25502

21 January 2018

Immunologic effects of hydroxyurea in sickle cell anemia

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25502

21 January 2018

Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life

1 reference

https://api.crossref.org/works/10.1002%2FPBC.25502

21 January 2018

Identifiers

10.1002/PBC.25502

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

release_lvmxzlg53vgtxpgheujwjfykjy

1 reference

https://api.fatcat.wiki/v0/release/lvmxzlg53vgtxpgheujwjfykjy

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41382795&oldid=2096774461"